Department of Medicine II, University Hospital Tuebingen, Tuebingen, Germany.
Department of Medicine II, University Hospital Tuebingen, Tuebingen, Germany.
Transplant Cell Ther. 2022 Aug;28(8):513.e1-513.e4. doi: 10.1016/j.jtct.2022.05.011. Epub 2022 May 14.
Cytomegalovirus (CMV) reactivation is common after allogeneic hematopoietic cell transplantation (HCT) and may result in fatal CMV disease. Invariant natural killer T (iNKT) cells are potent modulators of the immune system preventing graft-versus-host disease while promoting graft-versus-leukemia effects. It is thought that iNKT cells selectively influence mediators of both innate and adaptive immunity. Here, we investigated the impact of graft iNKT cells on CMV reactivation in patients undergoing allogeneic HCT. We found a significantly decreased cumulative incidence of CMV reactivation in patients with higher numbers of iNKT cells in the allograft. Therefore iNKT-cell-enriched grafts or adoptive transfer of iNKT cells are compelling cytotherapeutic strategies to improve outcomes after allogeneic HCT.
巨细胞病毒(CMV)再激活在异基因造血细胞移植(HCT)后很常见,可能导致致命的 CMV 疾病。不变自然杀伤 T(iNKT)细胞是免疫系统的强效调节剂,可预防移植物抗宿主病,同时促进移植物抗白血病效应。据认为,iNKT 细胞选择性地影响先天和适应性免疫的介质。在这里,我们研究了移植 iNKT 细胞对接受异基因 HCT 的患者 CMV 再激活的影响。我们发现,在同种异体移植物中 iNKT 细胞数量较高的患者,CMV 再激活的累积发生率显著降低。因此,iNKT 细胞富集的移植物或 iNKT 细胞的过继转移是改善异基因 HCT 后结果的有吸引力的细胞治疗策略。